Form 13-F position report

MERSANA THERAPEUTICS INC COM

Reported by MORGAN STANLEY

MRSN CUSIP 59045L106 Manager CIK 0000895421

Reported 307,130 shares, down 896,226 (74.5%) from the prior quarter.

Reported value -93.9%; share count -74.5% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q1 2025
Shares 307,130 Quarter-end amount reported
Reported value $105,715 Fair value at quarter end
Consecutive quarters held 31 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 7641000
2022-03-31 8663000
2022-06-30 7269000
2022-09-30 10779000
2022-12-31 10301799
2023-03-31 7803382
2023-06-30 2515242
2023-09-30 1252243
2023-12-31 9592147
2024-03-31 13183192
2024-06-30 4567914
2024-09-30 2578369
2024-12-31 1720799
2025-03-31 105715
2025-06-30 105849
2025-09-30 0
2025-09-30 375017
2025-12-31 535089
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for MERSANA THERAPEUTICS INC COM held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -18,496 (-100.0%) 0 $0 2026-05-15
Q4 2025 Reduced 18,496 -29,831 (-61.7%) < 0.01% $535,089 2026-02-13
Q3 2025 New 48,327 +48,327 (0.0%) < 0.01% $375,017 2025-11-14
Q3 2025 Reduced 0 -357,597 (-100.0%) 0 $0 2025-11-14
Q2 2025 Added 357,597 +50,467 (16.4%) < 0.01% $105,849 2025-08-15
Q1 2025 Reduced 307,130 -896,226 (-74.5%) < 0.01% $105,715 2025-05-15
Q4 2024 Reduced 1,203,356 -160,860 (-11.8%) < 0.01% $1,720,799 2025-02-14
Q3 2024 Reduced 1,364,216 -908,378 (-40.0%) < 0.01% $2,578,369 2024-11-14
Q2 2024 Reduced 2,272,594 -670,083 (-22.8%) < 0.01% $4,567,914 2024-08-14
Q1 2024 Reduced 2,942,677 -1,191,869 (-28.8%) < 0.01% $13,183,192 2024-05-15
Q4 2023 Added 4,134,546 +3,148,529 (319.3%) < 0.01% $9,592,147 2024-02-13
Q3 2023 Added 986,017 +221,506 (29.0%) < 0.01% $1,252,243 2023-11-15
Q2 2023 Reduced 764,511 -1,134,122 (-59.7%) < 0.01% $2,515,242 2023-08-14
Q1 2023 Added 1,898,633 +140,647 (8.0%) < 0.01% $7,803,382 2023-05-15
Q4 2022 Added 1,757,986 +163,412 (10.2%) < 0.01% $10,301,799 2023-02-14
Q3 2022 Added 1,594,574 +21,117 (1.3%) < 0.01% $10,779,000 2022-11-14
Q2 2022 Reduced 1,573,457 -597,916 (-27.5%) < 0.01% $7,269,000 2022-08-15
Q1 2022 Added 2,171,373 +942,887 (76.8%) < 0.01% $8,663,000 2022-05-13
Q4 2021 Added 1,228,486 +560,718 (84.0%) < 0.01% $7,641,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

159 managers reported MERSANA THERAPEUTICS INC COM for Q1 2025.

Managers reporting MERSANA THERAPEUTICS INC COM in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Nextech Invest Ltd New 12,067,246 +12,067,246 0.97% $4,153,546 1 qtr
Bain Capital Life Sciences Investors LLC Unchanged 8,663,673 0 0.44% $2,982,036 20 qtrs
VANGUARD GROUP INC Added 8,377,767 +1,320,251 < 0.01% $2,881,951 32 qtrs
BlackRock Inc Reduced 8,326,182 -879,000 < 0.01% $2,865,872 3 qtrs
Schonfeld Strategic Advisors LLC Added 7,614,064 +5,494,478 0.02% $2,620,760 8 qtrs
AQR CAPITAL MANAGEMENT LLC New 5,143,749 +5,143,749 < 0.01% $1,770,478 1 qtr
Rock Springs Capital Management LP Added 3,814,684 +383,000 0.08% $1,313,014 32 qtrs
VR Adviser LLC Reduced 3,574,325 -6,683,465 0.1% $1,230,283 7 qtrs
SILVERARC CAPITAL MANAGEMENT LLC New 3,088,505 +3,088,505 0.22% $1,063,063 12 qtrs
ACADIAN ASSET MANAGEMENT LLC New 2,989,659 +2,989,659 < 0.01% $1,028,000 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 15, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
300,704
Shared
0
None
6,426

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.